tetano
Editor, Senior Moderator
Life Sci Alliance
. 2022 Mar 7;5(6):e202101322.
doi: 10.26508/lsa.202101322. Print 2022 Jun.
Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern
Taishi Kondo[SUP] 1 [/SUP], Kazuhiro Matsuoka[SUP] 2 [/SUP], Shun Umemoto[SUP] 1 [/SUP], Tomoshige Fujino[SUP] 1 [/SUP], Gosuke Hayashi[SUP] 1 3 [/SUP], Yasumasa Iwatani[SUP] 4 5 [/SUP], Hiroshi Murakami[SUP] 1 6 [/SUP]
Affiliations
Abstract
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are useful for patients' treatment of the coronavirus disease 2019 (COVID-19). We report here affinity maturation of monobodies against the SARS-CoV-2 spike protein and their neutralizing activity against SARS-CoV-2 B.1.1 (Pango v.3.1.14) as well as four variants of concern. We selected matured monobodies from libraries with multi-site saturation mutagenesis on the recognition loops through in vitro selection. One clone, the C4-AM2 monobody, showed extremely high affinity (K [SUB]D[/SUB] < 0.01 nM) against the receptor-binding domain of the SARS-CoV-2 B.1.1, even in monomer form. Furthermore, the C4-AM2 monobody efficiently neutralized the SARS-CoV-2 B.1.1 (IC [SUB]50[/SUB] = 46 pM, 0.62 ng/ml), and the Alpha (IC [SUB]50[/SUB] = 77 pM, 1.0 ng/ml), Beta (IC [SUB]50[/SUB] = 0.54 nM, 7.2 ng/ml), Gamma (IC [SUB]50[/SUB] = 0.55 nM, 7.4 ng/ml), and Delta (IC [SUB]50[/SUB] = 0.59 nM, 8.0 ng/ml) variants. The obtained monobodies would be useful as neutralizing proteins against current and potentially hazardous future SARS-CoV-2 variants.
. 2022 Mar 7;5(6):e202101322.
doi: 10.26508/lsa.202101322. Print 2022 Jun.
Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern
Taishi Kondo[SUP] 1 [/SUP], Kazuhiro Matsuoka[SUP] 2 [/SUP], Shun Umemoto[SUP] 1 [/SUP], Tomoshige Fujino[SUP] 1 [/SUP], Gosuke Hayashi[SUP] 1 3 [/SUP], Yasumasa Iwatani[SUP] 4 5 [/SUP], Hiroshi Murakami[SUP] 1 6 [/SUP]
Affiliations
- PMID: 35256514
- DOI: 10.26508/lsa.202101322
Abstract
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are useful for patients' treatment of the coronavirus disease 2019 (COVID-19). We report here affinity maturation of monobodies against the SARS-CoV-2 spike protein and their neutralizing activity against SARS-CoV-2 B.1.1 (Pango v.3.1.14) as well as four variants of concern. We selected matured monobodies from libraries with multi-site saturation mutagenesis on the recognition loops through in vitro selection. One clone, the C4-AM2 monobody, showed extremely high affinity (K [SUB]D[/SUB] < 0.01 nM) against the receptor-binding domain of the SARS-CoV-2 B.1.1, even in monomer form. Furthermore, the C4-AM2 monobody efficiently neutralized the SARS-CoV-2 B.1.1 (IC [SUB]50[/SUB] = 46 pM, 0.62 ng/ml), and the Alpha (IC [SUB]50[/SUB] = 77 pM, 1.0 ng/ml), Beta (IC [SUB]50[/SUB] = 0.54 nM, 7.2 ng/ml), Gamma (IC [SUB]50[/SUB] = 0.55 nM, 7.4 ng/ml), and Delta (IC [SUB]50[/SUB] = 0.59 nM, 8.0 ng/ml) variants. The obtained monobodies would be useful as neutralizing proteins against current and potentially hazardous future SARS-CoV-2 variants.